Virchows Archiv

, Volume 471, Issue 6, pp 743–751 | Cite as

HCRP1 downregulation confers poor prognosis and induces chemoresistance through regulation of EGFR-AKT pathway in human gastric cancer

  • Hao Xu
  • Zhi-Feng Miao
  • Zhen-Ning Wang
  • Ting-Ting Zhao
  • Ying-Ying Xu
  • Yong-Xi Song
  • Jin-Yu Huang
  • Jun-Yan Zhang
  • Xing-Yu Liu
  • Jian-Hua Wu
  • Hui-Mian XuEmail author
Original Article


The current study aims to investigate the biological roles and clinical significance of HCRP1 in human gastric cancer. The expression pattern of HCRP1 in gastric cancer tissue and adjacent non-cancerous tissue was detected by immunohistochemistry. HCRP1 downregulation was found in 57 of 137 human gastric cancer samples and correlated with advanced TNM stage, positive nodal status, and relapse. Log-rank test showed that HCRP1 downregulation also correlated with poor overall survival and reduced relapse-free survival. In addition, we found that HCRP1 overexpression inhibited proliferation, colony formation, and invasion in HGC-27 cells. On the other hand, HCRP1 depletion by small interfering RNA promoted proliferation, colony formation, and invasion in SGC-7901 cells. We also treated gastric cancer cells with cisplatin. MTT and Annexin V/PI analysis were carried out to examine change of chemoresistance. We found that HCRP1 overexpression sensitized HGC-27 cells to cisplatin while its depletion reduced sensitivity in SGC-7901 cells. Moreover, we found that HCRP1 overexpression negatively regulated cyclin D1, MMP-2, p-EGFR, p-ERK, and p-AKT. HCRP1 depletion showed the opposite effects. In conclusion, our results suggest that HCRP1 downregulation might serve as an indicator for poor prognosis in gastric cancer patients. HCRP1 reduces drug resistance through regulation of EGFR-AKT signaling.


HCRP1 Gastric cancer Cell cycle Resistance 



We thank Prof. Feng Li for technical guidance and assistance.

Author contribution

Hao Xu and Zhi-Feng Miao designed the study and wrote the manuscript; Hao Xu and Zhen-Ning Wang collected the tissue sections; Hui-Mian Xu contributed to the study design and paper accomplishment; Ting-Ting Zhao and Ying-Ying Xu performed the MTT and flow cytometry assays; Hao Xu and Yong-Xi Song performed the cell culture, transfection, and western blot assays; Zhi-Feng Miao, Jin-Yu Huang, and Jun-Yan Zhang performed the immunohistochemistry, colony formation, and matrigel invasion assay; Xing-Yu Liu and Jian-Hua Wu analyzed the data. All authors participated in discussing the content of the paper and read and approved the final manuscript.


This work was supported by the National Science Foundation of China (grant numbers: 81272718 and 81302125).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

The protocols of this study have been approved by the Ethics committee of China Medical University (reference number 2016-AF-03).

Supplementary material

428_2017_2237_Fig6_ESM.gif (24 kb)
Supplementary Figure 1

Validation of antibody. HCRP1 antibody showed positive cytoplasmic staining in a case of normal gastric tissue. Using western blot, HCRP1 antibody detect a single band in this normal tissues and cells. The intensity decreased significantly in cells with HCRP1 depletion. (GIF 23 kb)

428_2017_2237_MOESM1_ESM.tif (303 kb)
High resolution image (TIFF 302 kb)


  1. 1.
    Merchant SJ, Kim J, Choi AH, Sun V, Chao J, Nelson R (2017) A rising trend in the incidence of advanced gastric cancer in young Hispanic men. Gastric Cancer 20(2):226–234. CrossRefPubMedGoogle Scholar
  2. 2.
    Roberts SE, Morrison-Rees S, Samuel DG, Thorne K, Akbari A, Williams JG (2016) Review article: the prevalence of Helicobacter pylori and the incidence of gastric cancer across Europe. Aliment Pharmacol Ther 43(3):334–345. CrossRefPubMedGoogle Scholar
  3. 3.
    Nicolas C, Sylvain M, Come L, Jean F, Anne-Marie B, Valérie J (2016) Trends in gastric cancer incidence: a period and birth cohort analysis in a well-defined French population. Gastric Cancer 19(2):508–514. CrossRefPubMedGoogle Scholar
  4. 4.
    Fujii H, Ichikawa K, Takagaki T, Nakanishi Y, Ikegami M, Hirose S, Shimoda T (2003) Genetic evolution of alpha fetoprotein producing gastric cancer. J Clin Pathol 56(12):942–949CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Polom K, Marano L, Roviello G, Petrioli R, Piagnerelli R, de Franco L, Marrelli D, Roviello F (2016) Evolution and emerging future of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion in gastric cancer: from treating the incurable to preventing recurrence. Int J Hyperth 32(2):173–179. CrossRefGoogle Scholar
  6. 6.
    You WC, Li JY, Blot WJ, Chang YS, Jin ML, Gail MH, Zhang L, Liu WD, Ma JL, Hu YR, Mark SD, Correa P, Fraumeni JF Jr, Xu GW (1999) Evolution of precancerous lesions in a rural Chinese population at high risk of gastric cancer. Int J Cancer 83(5):615–619CrossRefPubMedGoogle Scholar
  7. 7.
    Nadauld LD, Garcia S, Natsoulis G, Bell JM, Miotke L, Hopmans ES, Xu H, Pai RK, Palm C, Regan JF, Chen H, Flaherty P, Ootani A, Zhang NR, Ford JM, Kuo CJ, Ji HP (2014) Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer. Genome Biol 15(8):428. CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Mendes F (1951) Problems in the diagnosis and evolution of gastric cancer. Resen Clin Cient 20(6):187–197PubMedGoogle Scholar
  9. 9.
    Bache KG, Slagsvold T, Cabezas A, Rosendal KR, Raiborg C, Stenmark H (2004) The growth-regulatory protein HCRP1/hVps37A is a subunit of mammalian ESCRT-I and mediates receptor down-regulation. Mol Biol Cell 15(9):4337–4346. CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Xu J, Yang W, Wang Q, Zhang Q, Li X, Lin X, Liu X, Qin Y (2014) Decreased HCRP1 expression is associated with poor prognosis in breast cancer patients. Int J Clin Exp Pathol 7(11):7915–7922PubMedPubMedCentralGoogle Scholar
  11. 11.
    Perisanidis C, Savarese-Brenner B, Wurger T, Wrba F, Huynh A, Schopper C, Kornek G, Selzer E, Ewers R, Psyrri A, Krainer M, Filipits M (2013) HCRP1 expression status is a significant prognostic marker in oral and oropharyngeal cancer. Oral Dis 19(2):206–211. CrossRefPubMedGoogle Scholar
  12. 12.
    Xu Z, Liang L, Wang H, Li T, Zhao M (2003) HCRP1, a novel gene that is downregulated in hepatocellular carcinoma, encodes a growth-inhibitory protein. Biochem Biophys Res Commun 311(4):1057–1066CrossRefPubMedGoogle Scholar
  13. 13.
    Wittinger M, Vanhara P, El-Gazzar A, Savarese-Brenner B, Pils D, Anees M, Grunt TW, Sibilia M, Holcmann M, Horvat R, Schemper M, Zeillinger R, Schöfer C, Dolznig H, Horak P, Krainer M (2011) hVps37A status affects prognosis and cetuximab sensitivity in ovarian cancer. Clin Cancer Res 17(4):7816–7827. CrossRefPubMedGoogle Scholar
  14. 14.
    Xu J, Zhang X, Wang H, Ge S, Gao T, Song L, Wang X, Li H, Qin Y, Zhang Z (2017) HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition. Biomed Pharmacother 88:421–429. CrossRefPubMedGoogle Scholar
  15. 15.
    Du Y, Wang P, Sun H, Yang J, Lang X, Wang Z, Zang S, Chen L, Ma J, Sun D (2016) HCRP1 is downregulated in non-small cell lung cancer and regulates proliferation, invasion, and drug resistance. Tumour Biol.
  16. 16.
    Gao X, Fan L, Li H, Li J, Liu X, Sun R, Yu Z (2016) Hepatic injury is associated with cell cycle arrest and apoptosis with alteration of cyclin A and D1 in ammonium chloride-induced hyperammonemic rats. Exp Ther Med 11(2):427–434. CrossRefPubMedGoogle Scholar
  17. 17.
    Hosooka T, Ogawa W (2016) A novel role for the cell cycle regulatory complex cyclin D1-CDK4 in gluconeogenesis. J Diabetes Investig 7(1):27–28. CrossRefPubMedGoogle Scholar
  18. 18.
    Kim JY, Park SY, Lyoo HR, Koo ES, Kim MS, Jeong YS (2015) Extended stability of cyclin D1 contributes to limited cell cycle arrest at G1-phase in BHK-21 cells with Japanese encephalitis virus persistent infection. J Microbiol 53(1):77–83. CrossRefPubMedGoogle Scholar
  19. 19.
    Cheng G, Zhang L, Lv W, Dong C, Wang Y, Zhang J (2015) Overexpression of cyclin D1 in meningioma is associated with malignancy grade and causes abnormalities in apoptosis, invasion and cell cycle progression. Med Oncol 32(1):439. CrossRefPubMedGoogle Scholar
  20. 20.
    Wang Y, Dong QZ, Fu L, Stoecker M, Wang E, Wang EH (2013) Overexpression of CRKL correlates with poor prognosis and cell proliferation in non-small cell lung cancer. Mol Carcinog 52(11):890–899. CrossRefPubMedGoogle Scholar
  21. 21.
    Shimura T, Noma N, Oikawa T, Ochiai Y, Kakuda S, Kuwahara Y, Takai Y, Takahashi A, Fukumoto M (2012) Activation of the AKT/cyclin D1/Cdk4 survival signaling pathway in radioresistant cancer stem cells. Oncogene 1:e12. CrossRefGoogle Scholar
  22. 22.
    Kumar AP, Bhaskaran S, Ganapathy M, Crosby K, Davis MD, Kochunov P, Schoolfield J, Yeh IT, Troyer DA, Ghosh R (2007) Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract. Clin Cancer Res 13(9):2784–2794. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland 2017

Authors and Affiliations

  • Hao Xu
    • 1
  • Zhi-Feng Miao
    • 1
  • Zhen-Ning Wang
    • 1
  • Ting-Ting Zhao
    • 2
  • Ying-Ying Xu
    • 2
  • Yong-Xi Song
    • 1
  • Jin-Yu Huang
    • 1
  • Jun-Yan Zhang
    • 1
  • Xing-Yu Liu
    • 1
  • Jian-Hua Wu
    • 1
  • Hui-Mian Xu
    • 1
    Email author
  1. 1.Department of Surgical OncologyFirst Hospital of China Medical UniversityShenyangChina
  2. 2.Department of Breast SurgeryFirst Hospital of China Medical UniversityShenyangChina

Personalised recommendations